S
Sven Mahner
Researcher at Ludwig Maximilian University of Munich
Publications - 545
Citations - 12728
Sven Mahner is an academic researcher from Ludwig Maximilian University of Munich. The author has contributed to research in topics: Ovarian cancer & Medicine. The author has an hindex of 46, co-authored 439 publications receiving 9126 citations. Previous affiliations of Sven Mahner include Charité & University of Hamburg.
Papers
More filters
Journal ArticleDOI
Niraparib Maintenance Therapy in Platinum-Sensitive, Recurrent Ovarian Cancer
Mansoor Raza Mirza,Bradley J. Monk,Jørn Herrstedt,Amit M. Oza,Sven Mahner,Sven Mahner,Andrés Redondo,Michel Fabbro,Jonathan A. Ledermann,Domenica Lorusso,Ignace Vergote,Noa Ben-Baruch,Christian Marth,Radosław Mądry,René dePont Christensen,Jonathan S. Berek,Anne Dørum,Anne Dørum,Anna V. Tinker,Andreas du Bois,Antonio González-Martín,Philippe Follana,Benedict B. Benigno,Per Rosenberg,Lucy Gilbert,Bobbie J. Rimel,Joseph Buscema,John Balser,Shefali Agarwal,Ursula A. Matulonis,Ursula A. Matulonis +30 more
TL;DR: Among patients with platinum-sensitive, recurrent ovarian cancer, the median duration of progression-free survival was significantly longer amongThose receiving niraparib than among those receiving placebo, regardless of the presence or absence of gBRCA mutations or HRD status, with moderate bone marrow toxicity.
Journal ArticleDOI
ESMO-ESGO consensus conference recommendations on ovarian cancer: pathology and molecular biology, early and advanced stages, borderline tumours and recurrent disease
Nicoletta Colombo,Cristiana Sessa,A. du Bois,Jonathan A. Ledermann,WG McCluggage,Iain A. McNeish,P. Morice,Sandro Pignata,Isabelle Ray-Coquard,Ignace Vergote,Thaïs Baert,I. Belaroussi,A. Dashora,Siel Olbrecht,François Planchamp,Denis Querleu,Susana Banerjee,P. Blecharz,Ilan Bruchim,David Cibula,Nicole Concin,Ben Davidson,Mojgan Devouassoux-Shisheboran,Annamaria Ferrero,R.M. Glasspool,Antonio González-Martín,Viola Heinzelmann-Schwarz,Florence Joly,J. W. Kim,Frédéric Kridelka,Domenica Lorusso,Sven Mahner,Mikio Mikami,Mansoor Raza Mirza,Shibani Nicum,Dearbhaile M. O'Donnell,Patricia Pautier,Alexandros Rodolakis,Jalid Sehouli,Fatih Selcukbiricik,Naveena Singh,David S.P. Tan,Dirk Timmerman,Germana Tognon,J. van der Velden,Petronella O. Witteveen,AG Zeimet +46 more
TL;DR: The recommendations presented here are based on the best available evidence and expert agreement and are presented with a summary of evidence supporting each recommendation.
Journal ArticleDOI
Olaparib combined with chemotherapy for recurrent platinum-sensitive ovarian cancer: a randomised phase 2 trial
Amit M. Oza,David Cibula,Ana Oaknin Benzaquen,Christopher J. Poole,Ron H.J. Mathijssen,Gabe S. Sonke,Nicoletta Colombo,Jiří Špaček,Peter Vuylsteke,H. Hirte,Sven Mahner,Marie Plante,Barbara Schmalfeldt,Helen Mackay,Jacqui Rowbottom,Elizabeth S. Lowe,Brian Dougherty,J. Carl Barrett,Michael Friedlander +18 more
TL;DR: Progression-free survival was significantly longer in the olaparib plus chemotherapy group than in the chemotherapy alone group and the BRCA mutation status was known for 107 patients (either at baseline or determined retrospectively), and prespecified exploratory analyses included efficacy by BRCa mutation status, assessed retrospectively.
Journal ArticleDOI
A Randomized Trial of Lymphadenectomy in Patients with Advanced Ovarian Neoplasms
Philipp Harter,Jalid Sehouli,Domenica Lorusso,Alexander Reuss,Ignace Vergote,Christian Marth,Jae Weon Kim,Francesco Raspagliesi,Björn Lampe,Giovanni Aletti,Werner Meier,David Cibula,Alexander Mustea,Sven Mahner,IB Runnebaum,B Schmalfeldt,Alexander Burges,Rainer Kimmig,Giovanni Scambia,Stefano Greggi,Felix Hilpert,Annette Hasenburg,Peter Hillemanns,Giorgio Giorda,Ingo von Leffern,Carmen Schade-Brittinger,Uwe Wagner,Andreas du Bois +27 more
TL;DR: Systematic pelvic and paraaortic lymphadenectomy in patients with advanced ovarian cancer who had undergone intraabdominal macroscopically complete resection and had normal lymph nodes both before and during surgery was not associated with longer overall or progression‐free survival and was associated with a higher incidence of postoperative complications.
Journal ArticleDOI
Prospective Validation Study of a Predictive Score for Operability of Recurrent Ovarian Cancer: The Multicenter Intergroup Study DESKTOP II. A Project of the AGO Kommission OVAR, AGO Study Group, NOGGO, AGO-Austria, and MITO
Philipp Harter,Jalid Sehouli,Alexander Reuss,Annette Hasenburg,Giovanni Scambia,David Cibula,Sven Mahner,Ignace Vergote,Alexander Reinthaller,Alexander Burges,Lars Hanker,Martin Pölcher,Christian Kurzeder,Ulrich Canzler,Karl U. Petry,Andreas Obermair,Edgar Petru,Edgar Petru,Barbara Schmalfeldt,Domenica Lorusso,Andreas du Bois +20 more
TL;DR: This score is the first prospectively validated instrument to positively predict surgical outcome in recurrent ovarian cancer and will be enrolled in the recently started randomized prospective DESKTOP III trial investigating the role of surgery in recurrent platinum-sensitive ovarian cancer.